Clinical trials
Steatohepatitis clinical trials
Below are recruiting steatohepatitis clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07335601RecruitingPhase 2
Resmetirom for liver health after transplant in MASH patients
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
La Jolla, CaliforniaAges 18–75 - NCT07334080RecruitingPhase 1
Study of how food affects ECC4703 in healthy adults
This trial tests how taking the study drug ECC4703 with or without food affects its levels in the body, and how well the body absorbs it. It helps find the best way to take the drug.
Adelaide, South AustraliaAges 18–65 - NCT07325526RecruitingPhase 2
Testing an experimental drug for liver cirrhosis caused by MASH
This study tests an investigational medicine (BI 3802876) in people with early-stage liver cirrhosis due to MASH. The goal is to see if it is well tolerated and potentially helpful.
Chandler, ArizonaAges 18–75 - NCT07330830Recruiting
Genetics and fatty liver disease in Caribbean and Indian Ocean populations
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
CayenneAges 18 years+ - NCT07321925Recruiting
Using sound waves to measure liver fat
This study tests a new method that uses sound waves to measure fat in your liver. It could help doctors check liver health without a biopsy.
Ann Arbor, MichiganAges 18 years+ - NCT07313007Recruiting
Gut bacteria chemicals in fatty liver disease
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
Pierre-BéniteAges 18–80 - NCT07280143Recruiting
MASLD risk in breast or colorectal cancer survivors
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
BernAges 18 years+ - NCT07249788RecruitingPhase 4
Resmetirom for MASH: A study on safety and effectiveness
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
Rawalpindi, Punjab ProvinceAges 18–75 - NCT07239167Enrolling by invitation
Weight change study for adults with obesity
This study looks at how weight changes affect health in adults with obesity. You may qualify if you have a high BMI and are willing to try a weight loss program.
Taipei, Zhongzheng DistAges 18 years+ - NCT04501406RecruitingPhase 2
Low-dose pioglitazone for fatty liver disease in people with type 2 diabetes
This Phase 2 study tests whether low-dose pioglitazone can improve NASH, a type of fatty liver disease, in adults who also have type 2 diabetes. You may be able to join if your diabetes medicines and lab tests meet specific safety and stability requirements.
Gainesville, FloridaAges 21–75 - NCT06216041RecruitingPhase 1
Safety study of IMM-H014 in healthy adults
This trial tests a new drug called IMM-H014 in healthy volunteers to see if it is safe and how the body processes it. It also checks if food changes how the drug works. You may join if you are generally healthy and meet the age and weight requirements.
Changchun, JilinAges 18–45 - NCT07198386RecruitingPhase 2
Study of CS060380 tablets for NASH (fatty liver disease)
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
Fuzhou, FujianAges 18–70 - NCT07128797RecruitingPhase 1
Safety and tolerability of B1344 injections for NAFLD
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Beijing, Beijing MunicipalityAges 18–75 - NCT07099118RecruitingPhase 1
Safety and tolerability of HEC169584 in healthy people
This early-stage study checks if a new medicine called HEC169584 is safe for people and how it moves through the body. It looks for healthy volunteers to take part.
Beijing, Beijing MunicipalityAges 18–45 - NCT06975579Recruiting
Liver MRI scatter correction study
This study tests a new way to improve liver MRI images by reducing scatter. It includes healthy volunteers and patients with fatty liver disease (steatosis) having a regular liver MRI.
London, Greater LondonAges 18 years+ - NCT07070362Recruiting
Digital early warning system for lung injury after liver surgery
This trial tests a digital early warning system to detect acute lung injury after liver surgery. It may help doctors catch breathing problems early so they can treat them faster.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06986447Enrolling by invitation
Non-invasive tests for serious liver disease
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
Chandler, ArizonaAges 18–80 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06856252Recruiting
Studying human liver organoids for a fatty liver disease called NASH
This study takes small samples of liver tissue to grow 3D 'mini livers' (organoids) in the lab. Researchers want to learn how non-alcoholic steatohepatitis (NASH), a serious fatty liver condition, starts and progresses, which could lead to better treatments.
Milan, MilanoAges 18 years+ - NCT06819917Recruiting
Liver fibrosis test study for fatty liver disease
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
CopenhagenAges 18–75 - NCT06824974Recruiting
Time-restricted eating for liver disease or cancer
This study tests whether combining time-restricted eating with healthy eating helps people with metabolic liver disease, cirrhosis, or early-stage liver cancer. If you are overweight and currently fast less than 12 hours at night, this diet approach might improve your health.
La Jolla, CaliforniaAges 18 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Birmingham, AlabamaAges 18 years+ - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75
Hear when a new Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for steatohepatitis?
- Yes. Clin2 currently lists 93 recruiting steatohepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a steatohepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a steatohepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.